Enveric Biosciences, Inc. (ENVB)
| Market Cap | 41.80M |
| Revenue (ttm) | 35.41M |
| Net Income (ttm) | -6.86M |
| Shares Out | 5.75M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $1.91 |
| Previous Close | $1.90 |
| Change ($) | 0.01 |
| Change (%) | 0.53% |
| Day's Open | 1.90 |
| Day's Range | 1.85 - 2.00 |
| Day's Volume | 447,018 |
| 52-Week Range | 1.85 - 21.20 |
NAPLES, Fla., May 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve qualit...
NAPLES, FL / ACCESSWIRE / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality...
NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve qual...
NAPLES, Fla., April 1, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD)_medicines to i...
NEW YORK, March 18, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve qualit...
LOS ANGELES, CA / ACCESSWIRE / March 17, 2021 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with David Johnson, Chairman, and CEO of Enveric...
ORLANDO, Fla., March 16, 2021 /PRNewswire/ -- Diverse Biotech, Inc. www.diversebiotech.com announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive wo...
NAPLES, Fla., March 15, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve qual...
Enveric (ENVB) stock has purchased the exclusive rights to research molecules that could lead to huge breakthroughs in CBD cancer treatment. The post ENVB Stock: Why Little-Known Enveric Biosciences is ...
Enveric Biosciences Inc (NASDAQ: ENVB) soars in the premarket in reaction to acquiring an exclusive, perpetual license for novel molecules from Diverse Biotech. It is a biopharmaceutical company focused...
NAPLES, Fla., March 10, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve qual...
NAPLES, Fla., Feb. 25, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quali...
NAPLES, Fla., Feb. 9, 2021 /PRNewswire/ -- Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve q...
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
NAPLES, Fla., Jan. 15, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve...
NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology company e...
About ENVB
Enveric Biosciences, Inc., a biotechnology company, engages in developing various cannabinoid medicines to enhance quality of life for cancer patients. It has a pipeline of development programs for radiodermatitis, glioblastoma, and chemotherapy-induced neuropathy. The company is based in Naples, Florida.
| Industry Biotechnology | Founded 1994 |
| CEO Brent Kelton | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol ENVB |